Cabotegravir sodium

• CAT Number: I004230
• CAS Number: 1051375-13-3
• PubChem Substance ID: 46215800
• Molecular Formula: C19H16F2N3NaO5
• Molecular Weight: 428.34
• Purity: ≥95%
• IUPAC Name: N-(2,4-difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide, sodium salt
• InChI: InChI=1S/C19H17F2N3O5.Na/c1-9-8-29-14-7-23-6-12(16(25)17(26)15(23)19(28)24(9)14)18(27)22-5-10-2-3-11(20)4-13(10)21;/h2-4,6,9,14,26H,5,7-8H2,1H3,(H,22,27);/t9-,14+;/m0./s1
• InChIKey: NOSILXJBCIUPCT-KIUAEZIZSA-N
• SMILES: [Na].O=C(NCC1=CC=C(F)C=C1F)C2=CN3C(C(=O)N4C(OCC4C)C3)=C(O)C2=O

Cabotegravir sodium (CAT: I004230) is a long-acting integrase inhibitor that is used as a medication for the treatment of human immunodeficiency virus (HIV) infection. It works by inhibiting the activity of the integrase enzyme, which is essential for the replication of the virus. Cabotegravir sodium is administered by injection, and its long-acting properties allow for less frequent dosing, typically once every 4 to 8 weeks. This makes it a convenient and effective option for patients who have difficulty adhering to daily medication regimens. Cabotegravir sodium has been studied in clinical trials and has been shown to be highly effective in suppressing viral load in people living with HIV.